


Partnering Opportunity




CN Inhibitors a Different Approach

Calcineurin (CN) is the target of the immunosuppressant drugs cyclosporine and tacrolimus, which as suppressors of graft rejection are important treatments for posttransplant recovery. The use of these immunosuppressive drugs has revolutionized the transplant surgery in the last decades. However, their use on chronic pathological inflammatory diseases and other diseases where immunosuppressive is prescribed, have decreased due to side effects.

Many of the severe side effects of immunosuppressants (such as neurotoxicity, diabetes, nephrotoxicity, and hypertension) are mainly due to CN-independent processes including their binding to the cytosolic proteins cyclophilins.

Therefore, identifying selective CN inhibitors that avoid these secondary effects is of high interest.


Dr. Juan Miguel Redondo's research group has discovered a series of peptides that specifically inhibit the union between calcineurin and its target proteins such as the NFAT transcription factors. In that way, these molecules are viable candidates for the development of immunosuppressants with lower toxicity.



Technology Advantages

- **Therapeutic peptides** were designed from natural CN ligand.
- **Peptide interacts with CN** and inhibits its phosphatase activity.
- **Peptide blocks binding** of immunosuppressant drugs.
- **Lenti-peptide shows preventive and therapeutic effect** in rheumatoid arthritis mouse model.

Partnering Opportunity



Patent Status

- **WO2007074198**. Selective Peptides that Inhibit the Biological Activity of Calcineurin; US and EP applications. Priority date: 27/12/2006
- **New Indication for Peptides**. Under patent writing. Priority date: 12/11/2010

Looking for

- Licensing agreement.
- Partnership or collaboration for peptide delivery.

Product Profile

Attribute	Base case	Upside
Compound	Peptide	
Efficacy	Vs. known peptides and similar to CsA (but no toxic!)	Potential other autoimmune, transplant rejection.. and more!!*
Indication	RA	Potential other autoimmune, RA PoC pending
Safety	No evidence in vitro and lentiviral	
CoG	Peptide Synthesis	Just 15 aa
Patent Expiry	2025 EP, USA	+ Extensions * New Indication under patent writing

Contact:

Juan Miguel Redondo Moya

Scientific

jmredondo@cnic.es


Luzma García Piqueres

Management

luzma.garcia@cnic.es

+34 914 531 200

<http://www.cnic.es/en/inflamacion/>



Contact:

Diego Velasco Escribano

Project Manager

+34 914 491 250 EXT 041

diego.velasco@gen-es.org

<http://www.gen-es.org/>

Genoma
España

